CORRESP Filing
Liminatus Pharma, Inc.
Date: Feb. 11, 2026 · CIK: 0001971387 · Accession: 0001104659-26-013338
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293364
Letter
Re: Liminatus Pharma, Inc. ("Company")
February 11, 2026
Securities and Exchange Commission
100 F. Street, NE
Washington, D.C. 20549
Registration Statement on Form S-1
File No. 333-293364
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Maxim Group LLC, as placement agent, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 9:00 a.m., Washington D.C. time, on Friday, February 13, 2026, or as soon thereafter as practicable.
MAXIM GROUP LLC
By: /s/ Larry Glassberg
Name: Larry Glassberg
Title: Co-Head of Investment Banking
Show Raw Text
CORRESP
1
filename1.htm
February 11, 2026
Securities and Exchange Commission
100 F. Street, NE
Washington, D.C. 20549
Re:
Liminatus Pharma, Inc. ("Company")
Registration Statement on Form S-1
File No. 333-293364
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and
Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Maxim Group LLC, as placement
agent, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective
at 9:00 a.m., Washington D.C. time, on Friday, February 13, 2026, or as soon thereafter as practicable.
MAXIM GROUP LLC
By:
/s/ Larry Glassberg
Name:
Larry Glassberg
Title:
Co-Head of Investment Banking